Formulation Strategies and Particle Engineering Technologies for Pulmonary Delivery of Biopharmaceuticals

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

Formulation Strategies and Particle Engineering Technologies for Pulmonary Delivery of Biopharmaceuticals. / Cun, Dongmei; Wan, Feng; Yang, Mingshi.

In: Current Pharmaceutical Design, Vol. 21, No. 19, 2015, p. 2599-2610.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Cun, D, Wan, F & Yang, M 2015, 'Formulation Strategies and Particle Engineering Technologies for Pulmonary Delivery of Biopharmaceuticals', Current Pharmaceutical Design, vol. 21, no. 19, pp. 2599-2610. https://doi.org/10.2174/1381612821666150416100800

APA

Cun, D., Wan, F., & Yang, M. (2015). Formulation Strategies and Particle Engineering Technologies for Pulmonary Delivery of Biopharmaceuticals. Current Pharmaceutical Design, 21(19), 2599-2610. https://doi.org/10.2174/1381612821666150416100800

Vancouver

Cun D, Wan F, Yang M. Formulation Strategies and Particle Engineering Technologies for Pulmonary Delivery of Biopharmaceuticals. Current Pharmaceutical Design. 2015;21(19):2599-2610. https://doi.org/10.2174/1381612821666150416100800

Author

Cun, Dongmei ; Wan, Feng ; Yang, Mingshi. / Formulation Strategies and Particle Engineering Technologies for Pulmonary Delivery of Biopharmaceuticals. In: Current Pharmaceutical Design. 2015 ; Vol. 21, No. 19. pp. 2599-2610.

Bibtex

@article{a865f96e46e646dc9c10cbee2623181e,
title = "Formulation Strategies and Particle Engineering Technologies for Pulmonary Delivery of Biopharmaceuticals",
abstract = "Biopharmaceuticals including recombinant proteins, monoclonal antibody and nucleic acid based therapeutics have become more and more important to improve the quality of life of patients. However, the administration of biopharmaceuticals was mainly limited to parenteral routes and their delivery remains the most significant challeng to their clinical adoption due to their unfavorable intrinsic physicochemical properties. Among noninvasive administration routes the lung has been attempted intensively to be an alternative to injection to deliver the biopharmaceuticals, and has shown to be promising. In this review we discussed the formulation strategies and particle engineering technologies to improve the efficiency of pulmonary delivery of biopharmaceutical, with a focus on systemic therapy of pharmaceutical proteins/peptides and local delivery of siRNA via the lung administration. ",
keywords = "Pulmonary delivery, proteins and peptides, SiRNA, formulation strategy, particle engineering",
author = "Dongmei Cun and Feng Wan and Mingshi Yang",
year = "2015",
doi = "10.2174/1381612821666150416100800",
language = "English",
volume = "21",
pages = "2599--2610",
journal = "Current Pharmaceutical Design",
issn = "1381-6128",
publisher = "Bentham Science Publishers",
number = "19",

}

RIS

TY - JOUR

T1 - Formulation Strategies and Particle Engineering Technologies for Pulmonary Delivery of Biopharmaceuticals

AU - Cun, Dongmei

AU - Wan, Feng

AU - Yang, Mingshi

PY - 2015

Y1 - 2015

N2 - Biopharmaceuticals including recombinant proteins, monoclonal antibody and nucleic acid based therapeutics have become more and more important to improve the quality of life of patients. However, the administration of biopharmaceuticals was mainly limited to parenteral routes and their delivery remains the most significant challeng to their clinical adoption due to their unfavorable intrinsic physicochemical properties. Among noninvasive administration routes the lung has been attempted intensively to be an alternative to injection to deliver the biopharmaceuticals, and has shown to be promising. In this review we discussed the formulation strategies and particle engineering technologies to improve the efficiency of pulmonary delivery of biopharmaceutical, with a focus on systemic therapy of pharmaceutical proteins/peptides and local delivery of siRNA via the lung administration.

AB - Biopharmaceuticals including recombinant proteins, monoclonal antibody and nucleic acid based therapeutics have become more and more important to improve the quality of life of patients. However, the administration of biopharmaceuticals was mainly limited to parenteral routes and their delivery remains the most significant challeng to their clinical adoption due to their unfavorable intrinsic physicochemical properties. Among noninvasive administration routes the lung has been attempted intensively to be an alternative to injection to deliver the biopharmaceuticals, and has shown to be promising. In this review we discussed the formulation strategies and particle engineering technologies to improve the efficiency of pulmonary delivery of biopharmaceutical, with a focus on systemic therapy of pharmaceutical proteins/peptides and local delivery of siRNA via the lung administration.

KW - Pulmonary delivery

KW - proteins and peptides

KW - SiRNA

KW - formulation strategy

KW - particle engineering

U2 - 10.2174/1381612821666150416100800

DO - 10.2174/1381612821666150416100800

M3 - Journal article

VL - 21

SP - 2599

EP - 2610

JO - Current Pharmaceutical Design

JF - Current Pharmaceutical Design

SN - 1381-6128

IS - 19

ER -

ID: 161662065